<?xml version="1.0" encoding="UTF-8"?>
<p>In conclusion, several direct anti-SARS-CoV-2 agents have demonstrated some promising 
 <italic>in vitro</italic> and clinical efficacy (Fig. 
 <xref ref-type="fig" rid="F1">1</xref>). However, most of them are case reports or preliminary data from clinical trials with small sample sizes; therefore, further clinical trials are required. According to the current knowledge about the pandemic of SARS-CoV-2, the pharmacological development of direct-acting agents against COVID-19 is an urgent issue and a critical challenge for all of the pharmaceutical scientists and healthcare professionals.
</p>
